Optieum Biotechnologies
optieumbio.com
Actively hiring
Oncology Therapeutics
Cell & Gene Therapy
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$9M
1 round on record
Latest round
$9M
Series A · Jan 2025 · 20 mo ago
Team
51-200
employees, estimated range
Hiring now
1
open roles
The money's age
Due for its next round
20 months since the last round · hiring slowed
Momentum
15/100
in the news
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
May 8, 2025
Partnership Cellipont Bioservices and Optieum Biotechnologies Partner to Advance cGMP Manufacturing of Groundbreaking CAR-T Therapy for Glioblastoma · optieumbio.com
May 6, 2025
Partnership Genezen and Optieum Biotechnologies Partner to Support cGMP Manufacturing of Groundbreaking CAR-T Therapy for Glioblastoma · optieumbio.com
Jan 14, 2025
Raised a round Series A $9M
2020
Founded
Tractionpublic signals, read monthly
Web presence
top 9%
of 133.2M domains by links, Common Crawl
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Series A | Jan 2025 | $9M | — | optieumbio.com |
Similar startupsby what they do, their industry and backers
Learn about Lyell and how we are building an industry-leading clinical-stage pipeline of CAR-T cell product candidates for cancer.
BrainChild Bio is a kids-first, clinical-stage biotechnology company harnessing the power of CAR-T cell technology for tumors in the…
Autolus is a CAR T cell therapy company which develops advanced autologous T cell therapies that have the potential to deliver…
Umoja Biopharma pioneering immunotherapy by reprogramming T cells in vivo to target cancer cells and generate lasting remission.
The Next Generation in. OncoSenX is a late stage pre-clinical cancer company headquartered in Seattle, Washington. OncoSenX targets solid…
TwoStep Therapeutics. Developing tumor-targeted therapies with broad applicability across solid tumors.
News
CTI and Optieum Bio Announce Partnership to Advance Phase Ia / Ib CAR-T Therapy Program Targeting FAPα for Glioblastoma
Covington, KY, and Ehime, Japan, August 27, 2026 - CTI Clinical Trial & Consulting (CTI) and Optieum Biotechnologies (Optieum Bio) today announced a partnership to advance the clinical development of OPTF01, Optieum Bio's investigational CART-cell therapy
Read more
Report
Optieum Biotechnologies Advances to Stage 2 of AMED's Drug Discovery Venture Ecosystem Enhancement Program
Read more
Report
Optieum Biotechnologies Announces Upcoming Presentation at AACR Annual Meeting 2026
Presentation will feature preclinical data supporting Optieum's lead program OPTF01, demonstrating the ability of FAPα-targeted CAR-T cells to deplete FAPα-positive tumor cells and remodel the tumor microenvironmentEhime, Japan, April 10, 2026 - Optieum B
Read more
Report
Optieum Biotechnologies Appoints Dr. Sheila Singh as Clinical Advisor to Advance OPTF01 Clinical Strategy
Ehime, Japan, January 7, 2026 - Optieum Biotechnologies Inc. ("Optieum"), a biotechnology company focused on discovering and developing innovative CAR-T cell therapies, today announced the appointment of Dr. Sheila Singh, M.D., PhD, FRCSC, as Clinical Adv
Read more
Report
Cellipont Bioservices and Optieum Biotechnologies Partner to Advance cGMP Manufacturing of Groundbreaking CAR-T Therapy for Glioblastoma
Collaboration Leverages the OPTF01 product to Drive Next-Generation CAR-T Development The Woodlands, Texas and Ehime, Japan, May 8, 2025/ Cision / - Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO),
Read more
Report
Pro access
Upgrade to see all 10 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.
Growth
Hiring Momentum
28/100
Slowing
Open positions
1
0 opened / 0 closed in 30 days
ATS activity
Every ~12 hours
Today
Hiring Dynamics
0%
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Science & Research
100% ▼
Financials
Total raised
$9M
Latest round
Series A
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Series A | 2025 | $9M | Details |